Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Calcipotriene Foam · 1 trial · 1 indication
The investigator assessed participants with scalp psoriasis using the ISGA, scored as (as a visual average of lesions): 0, absence of disease; 1, very mild disease, lesions (L) with minimum erythema; 2, mild disease, L with light-red coloration, slight thickness, and fine, thin scale layer; 3, moderate disease, L with red coloration, moderate thickness, and a moderate scaled layer; 4, severe disease, L with red coloration, severe thickness, and a severe coarse, thick scale layer; 5, very severe disease, L with red coloration, very severe thickness, and a very severe, coarse, thick scale layer.
The investigator assessed participants with scalp psoriasis using the ISGA, scored as (as a visual average of lesions): 0, absence of disease; 1, very mild disease, lesions (L) with minimum erythema; 2, mild disease, L with light-red coloration, slight thickness, and fine, thin scale layer; 3, moderate disease, L with red coloration, moderate thickness, and a moderate scaled layer; 4, severe disease, L with red coloration, severe thickness, and a severe coarse, thick scale layer; 5, very severe disease, L with red coloration, very severe thickness, and a very severe, coarse, thick scale layer.
| Arm | Type | Description |
|---|---|---|
| Calcipotriene Foam | EXPERIMENTAL | Calcipotriene Foam 0.005%, |
| Vehicle Foam | PLACEBO_COMPARATOR | Vehicle Foam |
| Name | Type | Description |
|---|---|---|
| Calcipotriene Foam | DRUG | Calcipotriene Foam 0.005%. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group |
| Vehicle Foam | DRUG | Vehicle Foam. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group |
Inclusion Criteria: * Capable of understanding and willing to provide signed and dated written voluntary informed consent (and any local or national authorization requirements) before any protocol-specific procedures are performed. * Male or female subjects at least 12 years old and in good general...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 4 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
Calcipotriene foam is used to treat psoriasis, including psoriasis affecting both the scalp and the body. It is a topical small molecule therapy being developed by GSK plc under the ticker GSK. The Phase 3 program evaluated it in subjects with scalp and body psoriasis.
Calcipotriene foam works as an agonist of the vitamin D receptor, also known as VDR. By activating VDR, the small molecule modulates the biological pathways involved in psoriasis. This receptor agonist mechanism underlies its activity as a topical dermatology treatment.
Calcipotriene foam is developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor behind the clinical development of this topical small molecule for psoriasis in the dermatology therapeutic area.
Calcipotriene foam has reached Phase 3 clinical development. It is an investigational topical small molecule for psoriasis and is not described as approved. The Phase 3 trial has been completed, and no trials are currently listed as active.
Calcipotriene foam has been studied in the Phase 3 trial NCT01139580, titled a study to demonstrate the safety and effectiveness of calcipotriene foam in subjects with scalp and body psoriasis. It was a completed, randomized, double-blind, placebo-controlled trial that enrolled 363 participants in the United States.